Thompson Hine advises STERIS, and Ropes & Gray advises Becton, Dickinson and Company on the deal. STERIS plc (NYSE: STE) announced that the company has signed...
STERIS’ $540 Million Acquisition of BD’s Surgical Instrumentation Platform
Ovid Therapeutics’ Collaboration with Graviton Bioscience
Ropes & Gray advised Ovid Therapeutics on the deal. Ovid Therapeutics announced a collaboration with Graviton Bioscience Corporation under which Ovid obtained exclusive rights to develop...
Xeris Biopharma’s Research Collaboration with Regeneron Pharmaceuticals
Ropes & Gray represented Xeris Biopharma Holdings on the deal. Xeris Biopharma Holdings announced a platform research evaluation, collaboration and option agreement with Regeneron Pharmaceuticals, Inc....
ImmunoGen’s Global Multi-Target License and Option Agreement with Vertex
Ropes & Gray represented ImmunoGen, Inc. on the deal. ImmunoGen, Inc., a leader in the field of antibody-drug conjugates, announced a global, multi-target license and option agreement...
Amarin’s License and Distribution Agreement with CSL Seqirus
Ropes & Gray represented Amarin Corporation plc on the deal. Pharmaceutical company Amarin Corporation plc announced an agreement with CSL Seqirus for an exclusive license and distribution...
TRexBio’s Collaboration and License Agreement with Lilly
Ropes & Gray advised TRexBio on the deal. TRexBio in a multi-year research collaboration and exclusive worldwide license agreement with Eli Lilly and Company to develop...
ImmunoGen’s Collaboration with Gilead
Ropes & Gray advised ImmunoGen on the deal. ImmunoGen, a leader in the field of antibody-drug conjugates for cancer treatment, in a clinical collaboration with Gilead...
Xeris Biopharma’s Research Collaboration with Horizon Therapeutics
Ropes & Gray represented Xeris Biopharma on the deal. Xeris Biopharma announced a research collaboration and option agreement with Horizon Therapeutics. Under the agreement announced on November...
Cambrex’s Acquisition of Snapdragon Chemistry
Ropes & Gray advised Cambrex on the deal. Cambrex, a global contract development manufacturing organization (CDMO) providing products and services across the entire drug lifecycle, signed a...
Blackstone’s $1 Billion Financing Collaboration with PTC Therapeutics
WilmerHale advised PTC Therapeutics, while Ropes & Gray advised Blackstone on the deal. Blackstone announced a strategic financing collaboration for up to $1 billion in funding...
IDRx’s $122 Million Series A Financing
Ropes & Gray advised IDRx on the deal. Clinical stage precision cancer biopharmaceutical company IDRx announced licensing transactions with Germany-based Merck KGaA and Blueprint Medicines to...
EQRx’s Drug Collaboration with Aurigene
Ropes & Gray represented EQRx in the transaction. EQRx announced a strategic drug creation, development, and commercialization collaboration with Aurigene Discovery Technologies Limited to develop drug...